Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

✍ Scribed by M.R. Ranson; S. Cheeseman; S. White; J. Margison

• Publisher: Elsevier Science
• Year: 2001
• Tongue: English
• Weight: 77 KB
• Volume: 37
• Category: Article
• ISSN: 1040-8428
• DOI: 10.1016/s1040-8428(00)00107-4

✦ Synopsis

Anthracyclines are amongst the most active drugs in the treatment of breast cancer. Stealth liposomal doxorubicin (Caelyx, Doxil, Alza Pharmaceuticals Inc.) is a promising new agent under investigation for the treatment of breast cancer and other solid tumours. The liposomal encapsulation alters drug pharmacokinetics and leads to a marked change in toxicity profile compared to non-liposomal doxorubicin. The results of recently completed and ongoing clinical trials in breast cancer are reviewed.